MK-677 and Sleep: What Human Studies Actually Show

MK-677 (ibutamoren) is an investigational, orally active growth-hormone secretagogue. It acts through the ghrelin receptor and can increase growth hormone (GH) and insulin-like growth factor 1 (IGF-1) signalling. It is often discussed online as a sleep or recovery compound, but the human evidence is much narrower than those claims suggest.

This review focuses on the study design, measured sleep outcomes, safety limitations, and Canadian regulatory context. It does not provide dosing, cycle, or human-use guidance.

Key conclusions

The most directly relevant sleep trial was small: eight young adults and six older adults completed short crossover treatment periods.
That study measured sleep-stage changes under laboratory conditions; it did not establish treatment of chronic insomnia, improved athletic recovery, fat loss, or long-term health outcomes.
Other trials show that MK-677 can increase GH and IGF-1, but hormone changes should not be treated as proof of a clinical benefit.
Longer and medically focused studies have reported adverse metabolic effects, and one hip-fracture trial was stopped early after a congestive-heart-failure safety signal in a limited number of participants.
Health Canada lists ibutamoren among drugs marketed as SARMs and states that SARMs have not been authorized in Canada for medical use.

What MK-677 is – and is not

MK-677 is not a selective androgen receptor modulator. It is a non-peptide growth-hormone secretagogue that stimulates the ghrelin receptor. Because it affects GH and IGF-1 pathways, it has been investigated in settings such as ageing, body composition, hip-fracture recovery, and other clinical research questions.

Classifying the compound correctly matters. Evidence about androgen-receptor modulators cannot be transferred automatically to a ghrelin-receptor agonist, and neither category should be treated as an approved sleep supplement.

The small human sleep study

A 1997 double-blind crossover study is the source behind many MK-677 sleep claims. Eight healthy young adults completed three seven-day treatment periods, while six older adults completed two fourteen-day periods. Investigators used objective sleep-stage measurements and reported changes in stage IV and rapid-eye-movement (REM) sleep under one study condition.

The study is useful as an early mechanistic signal, but it has major limits:

The total sample was 14 people, split across two age groups.
Treatment periods were short.
The participants were not a representative chronic-insomnia population.
The trial was not designed to test exercise recovery, muscle gain, fat loss, skin or hair changes, or day-to-day functional improvement.
A sleep-stage change does not by itself establish that a person feels or functions better.

For those reasons, the paper supports further research; it does not support broad claims that MK-677 reliably improves sleep or recovery.

GH and IGF-1 findings are not the same as outcomes

A separate randomized study in 32 healthy older adults found that short-term MK-677 exposure increased pulsatile GH release and serum IGF-1. These are pharmacodynamic findings showing that the compound engaged its intended pathway. They do not prove better sleep, athletic recovery, tissue regeneration, or a favourable long-term risk-benefit profile.

The ClinicalTrials.gov record for a longer study in older adults likewise focused on GH, IGF-1, body composition, and functional ability. The population, endpoints, and controlled investigational material differ substantially from unsupervised use or products obtained through an unverified supply chain.

Safety and uncertainty

Safety must be assessed from more than the small sleep experiment. In a randomized phase IIb trial involving older adults recovering from hip fracture, several functional outcomes did not improve and the trial was terminated early after a congestive-heart-failure safety signal in a limited number of participants. Findings in older clinical populations cannot be transferred directly to every other population, but they are relevant evidence against treating the compound as low-risk.

Growth-hormone and IGF-1 signalling also interact with glucose regulation, fluid balance, appetite, and other physiological systems. The available studies do not establish the long-term safety of recreational exposure, multi-compound combinations, or products whose identity and concentration have not been independently verified.

Canadian regulatory context

Health Canada’s current bodybuilding-products guidance states that SARMs have not been authorized in Canada for medical use and identifies ibutamoren among drugs that may be marketed as SARMs. Authorized prescription drugs in Canada carry an eight-digit Drug Identification Number (DIN). A “research use only” statement does not establish authorization as a medicine or sleep product.

For a broader compound summary, read our MK-677 human-evidence and safety review. The Complete SARMs Research Guide explains the distinction between SARMs and adjacent research compounds. For analytical records, see the COA and testing documentation guide.

How to read future MK-677 research

Check whether the outcome is a sleep stage, a subjective sleep score, daytime function, or a clinical endpoint.
Confirm sample size, age, health status, study duration, and comparator.
Separate hormone changes from demonstrated patient benefit.
Review adverse events, laboratory changes, withdrawals, and follow-up duration.
Confirm compound identity and lot-level analytical documentation before interpreting any experimental result.

References

Research and regulatory information only. This article is not medical advice and does not recommend human use.